Bringing the fundamentals into focus…
Back to Neurocrine Biosciences, Inc.
How Neurocrine Biosciences, Inc. stacks up
NBIX · against 552 other Healthcare companies listed in US-listed
Overall
75/ 100
Near the top of its peers.
Ranked #24 of 553 · scores higher than 95% of peers
Bars: peers in each 10-point band of the overall score33 peers with an overall score of 70–79, including NBIX · Click a bar to see the companies
The four scores behind it
Overall = average of valuation, growth, profitability and safety percentile (categories without data are skipped)Ranking by overall score
Top 5 and the companies ranked around NBIX| Rank | Company | Market cap | Overall | Valuation | Growth | Profitability | Risk |
|---|---|---|---|---|---|---|---|
| 1 | 595M USD | 97 | 96 | 98 | 99 | 0 / 2 | |
| 1 | 261M USD | 97 | 93 | — | 98 | 0 / 2 | |
| 3 | 2.1B USD | 96 | 96 | 99 | 93 | 0 / 2 | |
| 4 | 1.5B USD | 93 | 94 | 91 | 93 | 0 / 2 | |
| 5 | 609M USD | 91 | 95 | 99 | 99 | 0 / 2 | |
| 21 | 1.7B USD | 77 | 89 | 89 | 85 | 1 / 2 | |
| 21 | 913M USD | 77 | 90 | 88 | 93 | 1 / 2 | |
| 23 | 17.9B USD | 76 | 67 | 68 | 99 | 0 / 2 | |
| 24 | 3.5B USD | 75 | 82 | 80 | 80 | 1 / 2 | |
| 24 | 16.8B USD | 75 | 64 | 87 | 91 | 1 / 2 | |
| 24 | 1.2B USD | 75 | 96 | 84 | 99 | 2 / 2 | |
| 24 | 884M USD | 75 | 63 | 94 | 49 | 0 / 2 | |
| 24 | 25.8B USD | 75 | 70 | 53 | 95 | 0 / 2 | |
| 29 | 5.2B USD | 74 | 37 | — | 91 | 0 / 2 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score